A critical aspect of this program project includes evaluating antibodies for their potency against HIV and affinities to gpl 20s and Fc receptors. The Cell/Biochemical Assay Automation Core will design and carry out cell-based and biochemical assays to characterize the specificity, efficacy, and potency of HIV-neutralizing antibodies. We have adapted the standard in vitro pseudovirus neutralization assay, which measures the reduction in luciferase reporter gene expression in the presence of a potential inhibitor following pseudovirus infection in TZM-bl cells, for execution by a liquid handing robot. Core A personnel will validate, refine, and trouble-shoot protocols for the automated in vitro neutralization assays and then perform automated in vitro neutralization assays for evaluating antibodies for Drs. Nussenzweig, Ravetch, and Bjorkman. In addition. Core A will perform rapid and high-throughput binding assays to assess the affinities of antibodies for gpl20s and/or gp140s, as required for Drs. Nussenzweig and Bjorkman, and the affinities of modified Fc regions for Fc receptors, as required by Dr. Ravetch. The core will train and assist students, postdoctoral fellows, research assistants, and investigators in the analysis and interpretation of data from automated assays. In addition, the core will maintain two custom-equipped Evo Freedom Liquid handling stations, including daily calibration and care, and annual preventative maintenance.

Public Health Relevance

HIV/AIDS is a global public health problem. Efforts to develop a vaccine or improve antibodies for passive immunization require screening large numbers of potential reagents: using in vitro neutralization assays to evaluate antibody potencies and protein-protein binding assays to identify interactions. We have automated these techniques in order to efficiently evaluate large numbers of reagents for the investigators in this collaborative project.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RRS-A (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
California Institute of Technology
United States
Zip Code
Scheid, Johannes F; Horwitz, Joshua A; Bar-On, Yotam et al. (2016) HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535:556-60
Lu, Ching-Lan; Murakowski, Dariusz K; Bournazos, Stylianos et al. (2016) Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352:1001-4
Escolano, Amelia; Steichen, Jon M; Dosenovic, Pia et al. (2016) Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell 166:1445-1458.e12
McGuire, Andrew T; Gray, Matthew D; Dosenovic, Pia et al. (2016) Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun 7:10618
Gautam, Rajeev; Nishimura, Yoshiaki; Pegu, Amarendra et al. (2016) A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533:105-9
Zolla-Pazner, Susan; Cohen, Sandra Sharpe; Boyd, David et al. (2016) Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. J Virol 90:636-49
Halper-Stromberg, Ariel; Nussenzweig, Michel C (2016) Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J Clin Invest 126:415-23
Steichen, Jon M; Kulp, Daniel W; Tokatlian, Talar et al. (2016) HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity 45:483-96
Gristick, Harry B; von Boehmer, Lotta; West Jr, Anthony P et al. (2016) Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat Struct Mol Biol 23:906-915
Scharf, Louise; West, Anthony P; Sievers, Stuart A et al. (2016) Structural basis for germline antibody recognition of HIV-1 immunogens. Elife 5:

Showing the most recent 10 out of 38 publications